Lucem Health
- Company typePrivate
- Founded2021
- HeadquartersRaleigh, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Lucem Health does
Lucem Health is a privately held healthcare AI company founded in 2021 in Raleigh, North Carolina, that builds AI-powered early disease detection software for U.S. healthcare providers and life sciences companies. The core product, Lucem Health Reveal, analyzes existing electronic health record data—including demographic, laboratory, medication, comorbidity, and encounter information—using validated clinical machine learning models to identify patients at higher statistical risk for undiagnosed serious diseases. The platform comprises disease-specific modules covering arrhythmias, atrial fibrillation–related stroke, colorectal cancer, lung cancer, liver disease (MASLD/MASH), and Type 1 diabetes, and is designed to integrate into existing clinical workflows without requiring process changes.
The company monetizes through enterprise subscriptions from health systems, hospitals, accountable care organizations, and integrated delivery networks, and through its Life Sciences Accelerate Program and Disease Insights module, which provide pharma and medical device partners with AI-driven post-market patient identification and market-access analytics. Distribution is sales-led and direct, supplemented by strategic channel partnerships with device and pharmaceutical companies such as iRhythm Technologies and Sanofi, and the company is co-founded with Mayo Clinic, which serves as both an investor and reference customer alongside Mercy Hospital St. Louis. Validation data is cited across 14M patient records and 442M encounters, with reported performance advantages such as up to 8x colorectal cancer detection, 47x Type 1 diabetes screening efficiency, and 3x liver disease screening efficiency versus standard approaches.
The business is at an early commercial stage: roughly $10M in total disclosed funding ($7.7M in May 2023 led by Granger Management and Mayo Clinic with Rally Ventures, plus $2.3M in August 2025), 11–50 employees, SOC 2 Type 2 compliance, and recognition including the 2025 Digital Health Hub Rising Star for AI in Health Operations. Revenue is not publicly disclosed, pricing is not listed, and only two enterprise customers are named, indicating the company is in early commercialization despite a mature product surface and validated clinical claims.
Lucem Health firmographics
Firmographics- Name
- Lucem Health
- Legal name
- Lucem Health
- Website
- https://lucemhealth.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Lucem Health industry classification
Industry- Product category
- Clinical Decision Support AI
- NAICS
- Other Computer Related Services (541519)
- SIC
- Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Risk Stratification, Early Warning Scores & Predictive Analytics (HLACAGAE)
- akta.pro secondary industries
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Quality Measurement, Reporting & Benchmarking (HEDIS/Stars/CQM) (HLACAHAC)
Keywords
Where Lucem Health is headquartered
LocationHeadquarters
- HQ city
- Raleigh
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Lucem Health business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Healthcare Provider Subscriptions: Subscription-based revenue from healthcare provider organizations accessing Reveal early disease detection programs. Providers pay for AI-powered solutions that improve patient outcomes and deliver ROI.
- Life Sciences Partnerships: Revenue from life sciences companies participating in the Accelerate Program, which helps partners expand market opportunities and optimize market access strategies.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Lucem Health product offering
Product offeringCore offering
Lucem Health develops and sells an AI-powered early disease detection platform (Lucem Health Reveal) that analyzes existing electronic health record (EHR) data using validated clinical machine learning models to identify patients at higher statistical risk for serious undiagnosed diseases such as arrhythmias, colorectal cancer, liver disease, lung cancer, stroke, and Type 1 diabetes. The platform is sold to healthcare providers (health systems, hospitals, ACOs) and to life sciences companies via a complementary Disease Insights analytics offering and the Accelerate Program.
Product overview
Lucem Health offers a unified platform-plus-modules architecture centered on its core Lucem Health Reveal early disease detection platform. Reveal is powered by validated clinical AI models that analyze existing EHR data to identify patients at higher statistical risk for undiagnosed diseases. The platform includes disease-specific sub-products: Reveal for Arrhythmias, Reveal for Colorectal Cancer, Reveal for Liver Disease, Reveal for Lung Cancer, Reveal for T1D, and Reveal for Stroke. Complementing Reveal is the Disease Insights add-on module for life sciences companies, which provides market access analytics including diagnostic pathways, provider trends, and patient outcomes data. The Accelerate Program enables life sciences partners to expand patient access through the Reveal solutions.
Differentiator
Problem solved
Functional benefit
Brands
- Reveal: AI-powered early disease detection platform that surfaces patients at higher risk of serious diseases before they become life-threatening. Includes solutions for arrhythmias, colorectal cancer, liver disease, lung cancer, stroke, and Type 1 Diabetes.
- Reveal for Arrhythmias
- Reveal for Colorectal Cancer
- Reveal for Liver Disease
- Reveal for Lung Cancer
- Reveal for T1D
- Disease Insights
- Accelerate Program
Products and services
- Lucem Health Reveal AI-powered early disease detection platform that analyzes existing EHR data to identify patients at higher statistical risk for serious undiagnosed diseases, enabling proactive care delivery programs without requiring workflow changes. Sold to healthcare providers and life sciences companies.
- Reveal for Arrhythmias AI solution that identifies patients at elevated risk for arrhythmias by analyzing EHR data, targeting populations with comorbid conditions such as Type 2 diabetes, chronic kidney disease, COPD, and coronary artery disease; integrates with iRhythm's Zio ECG monitoring.
- Reveal for Colorectal Cancer AI-powered early detection solution that identifies patients at higher statistical risk for colorectal cancer and other lower GI disorders, achieving up to 8x improved detection rates versus standard approaches.
- Reveal for Liver Disease AI-enabled solution that sifts through EHRs to identify individuals at higher statistical risk of undiagnosed MASLD or MASH by analyzing demographic, laboratory, medication, and comorbidity data; achieves 3x improved liver disease detection.
- Reveal for Lung Cancer AI solution that analyzes existing EHR data to identify patients showing higher statistical risk of lung and trachea cancers, enabling earlier screening and intervention for at-risk populations.
- Reveal for T1D AI and EHR-based solution to identify early-stage Type 1 Diabetes before DKA onset, achieving up to 47x improved screening efficiency; backed by Sanofi partnership.
- Reveal for Stroke AI solution designed to identify patients with undiagnosed atrial fibrillation (AFib) and higher risk of AFib-related strokes by analyzing ECG and EHR data.
- Disease Insights
Quantifiable outcome
- Up to 8x improved colorectal cancer detection
- +4 more outcomes
Companies that use Lucem Health
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Lucem Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature9 records
Lucem Health partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- iRhythm TechnologiescoreStrategic partnership combining Lucem Health's Reveal for Arrhythmias analytics with iRhythm's proven Zio ECG technology. The integration creates a seamless solution designed to shift cardiac care from reactive diagnosis to predictive, data-driven intervention. iRhythm's Zio device provides extended ambulatory cardiac monitoring capable of up to 14 days of continuous data collection, powered by an FDA-cleared AI algorithm. The joint commercial offering is designed for integration into ACO and health system workflows committed to value-based care.
- Mayo CliniccoreCo-founding partner of Lucem Health. The company was founded with Mayo Clinic and has developed its clinical AI platform in partnership with the renowned healthcare institution. Mayo Clinic Platform serves as a trusted customer and reference for the company's solutions. John Halamka, M.D., President of Mayo Clinic Platform, has provided endorsement: 'the development of AI and machine learning algorithms has the potential to revolutionize diagnostic medicine – and Lucem Health is paving the way.'
- SanoficoreBacker of Lucem Health's Reveal for T1D initiative launched in September 2025. Sanofi provided support for the development of AI-powered early detection of Type 1 Diabetes using EHR data to identify early-stage T1D, helping reduce preventable DKA and improve follow-up care.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Lucem Health competitors and assessment
Company assessmentDirect peers
- Medial EarlySign: Medial EarlySign develops AI models that analyze EHR data to identify patients at risk of undiagnosed disease, including oncology and metabolic conditions — a directly comparable early-detection AI approach. Lucem Health already collaborates with EarlySign on data science roundtables, underscoring product overlap.
- Jvion: Jvion is a clinical AI vendor focused on risk stratification and patient-level predictive analytics using EHR and claims data for hospitals and health systems. It competes head-to-head with Reveal in surfacing at-risk patients ahead of clinical deterioration.
- ClosedLoop.ai: ClosedLoop builds healthcare-specific AI/ML platforms for risk prediction, population health, and value-based care, including CMS-approved models. It is a close peer in targeting ACOs and providers with AI-driven early identification workflows.
- Mendel (Mendel Health): Mendel applies AI to clinical and biomedical data to identify patient cohorts and accelerate research and clinical workflows. It overlaps with Lucem's Disease Insights and Accelerate Program capabilities for life sciences customer identification.
Broad incumbents
- Health Catalyst: Health Catalyst is a large healthcare data and analytics platform with AI-augmented clinical and operational analytics deployed across health systems. It is a broader incumbent competitor that can bundle AI risk models with its enterprise data warehouse.
- Tempus Labs: Tempus is a large clinical AI company combining molecular data with AI-driven insights for providers and life sciences. It overlaps with Lucem's life sciences commercialization motion and competes for the same health system and pharma budgets.
- LeanTaas: LeanTaas provides AI-driven analytics and operational solutions for hospitals and health systems, including capacity, staffing, and patient flow. It competes with Lucem for AI budget within enterprise healthcare buyers, albeit with an operations rather than clinical-disease focus.
Emerging players
- Deep 6 AI: Deep 6 AI uses AI on EHR data to find eligible patients for clinical trials and care programs. It overlaps with Lucem's patient identification wedge, particularly for life sciences trial acceleration use cases adjacent to Accelerate.
- Iterative Health: Iterative Health applies AI to gastroenterology imaging and clinical workflows. It is an adjacent emerging player that deepens AI in a single specialty (GI), illustrating the depth-versus-breadth trade-off Lucem faces across its multi-disease Reveal portfolio.
Others
- H1 (H1.co): H1 is a healthcare data platform connecting life sciences companies to providers, clinicians, and patient populations. It is a thematically related ecosystem participant for Lucem's life sciences commercialization motion, though not a direct AI diagnostic competitor.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Lucem Health social profiles
Digital presenceLucem Health compliance and trust
Trust signalCompliance1 record
Lucem Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lucem Health leadership team
Management profileNumber of profiles
Profiles4 records
Lucem Health funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lucem Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lucem Health
What does Lucem Health do?
Lucem Health develops and sells an AI-powered early disease detection platform (Lucem Health Reveal) that analyzes existing electronic health record (EHR) data using validated clinical machine learning models to identify patients at higher statistical risk for serious undiagnosed diseases such as arrhythmias, colorectal cancer, liver disease, lung cancer, stroke, and Type 1 diabetes. The platform is sold to healthcare providers (health systems, hospitals, ACOs) and to life sciences companies via a complementary Disease Insights analytics offering and the Accelerate Program.
Is Lucem Health a public or private company?
Lucem Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was Lucem Health founded?
Lucem Health was founded in 2021. It employs 11 to 50 people.
Where is Lucem Health based?
Lucem Health is headquartered in Raleigh, United States, in the North America region.
How does Lucem Health make money?
Two revenue lines are on record. Healthcare Provider Subscriptions are the primary driver. The others are life Sciences Partnerships.
Who are Lucem Health's main competitors?
Direct peers on record are Medial EarlySign, Jvion, ClosedLoop.ai and Mendel (Mendel Health). Broad incumbents are Health Catalyst, Tempus Labs and LeanTaas. Emerging players are Deep 6 AI and Iterative Health. H1 (H1.co) is listed as an others.
Does Lucem Health have an API?
No public API is recorded for Lucem Health.
What industry is Lucem Health in?
Lucem Health's product category is Clinical Decision Support AI. Its primary akta.pro industry code is HLACAGAE, Risk Stratification, Early Warning Scores & Predictive Analytics, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 541519 and its SIC code is 7370.